# **Key Information Document**

### **Evolutif**

# A sub-fund of DNCA Invest SICAV

Share class: C (EUR) - ISIN: LU2661119755



### **Purpose**

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

#### **Product**

Product name: Evolutif

Evolutifis a sub-fund of DNCA Invest SICAV regulated by Luxembourg Law.

Name of the manufacturer: DNCA Finance ISIN: LU2661119755

Manufacturer's website: www.dnca-investments.com

Phone: For further information call +33158625500

This Product is managed by DNCA Finance, authorized in France under n°GP00030 and regulated by the Autorité des marchés financiers. This Product is authorised in Luxembourg and regulated by the Commission de Surveillance du Secteur Financier.

Further information is available on the Management Company's website: www.dnca-investments.com.

Key Information Document production date: 30/08/2024.

## What is this product?

#### TYPE

This Product is a sub-fund of DNCA Invest SICAV, an investment company with variable capital regulated by Luxembourg law and qualifying as UCITS pursuant to Directive 2009/65/CE.

#### **TERM**

The Product is established for an unlimited duration and liquidation must be decided upon by the Board of Directors.

#### **OBJECTIVES**

The Product seeks to outperform the 25% MSCI World NR EUR + 25 MSCI Europe NR EUR + 50% Bloomberg Euro Govt Inflation Linked 1-10 years composite index calculated dividends reinvested, over the recommended investment period, while protecting the capital during adverse periods through opportunistic management and flexible asset allocation. Investors' attention is drawn to the fact that the management style is discretionary and integrates environmental, social/societal and governance (ESG) criteria.

The Product is managed taking into consideration responsible and sustainable principles and promotes environmental and/or social characteristics within the meaning of Article 8 of SFDR. The investment process take into account internal scoring based on an extra-financial analysis through a proprietary rating model (ABA, Above & Beyond Analysis) developed internally by DNCA. The risk exists that the models used to make these investment decisions do not perform the tasks they were designed to. The use of the proprietary tool relies on the experience, relationships and expertise of DNCA with the "best in universe" method. There may be a sector bias. The Product will proceed to the extra-financial analysis on at least 90% of its securities, while excluding 20% of the worst issuers from its investment universe. Additional information on SRI strategy may be obtained in the prospectus of the Product. The Product's investment strategy relies on active discretionary management using a stock picking policy. This policy is all based on fundamental analysis developed through main investment criteria such as market assessment, issuer's financial structure, management quality, issuer's market position or regular contacts with issuers. The Management Company can use different methods to detect future investment returns as valuation metrics (PE, EV/EBIT, FCF yield, dividend yield...), sum of the parts or discounted cash-flows. The Product will be invested either in equities, bonds or money market instruments by adapting the investment strategy to the economic situation and the Management Company's expectations. Up to 100% of its net assets, the Product can be exposed to shares of issuers in all market capitalisation without geographical constraint. Shares of issuers with capitalisation below 1 billion euros may not exceed 10% of net assets. The part of investment in shares of companies having their registered office in emerging countries (such as but not limited to Asian countries except Japan or South America, etc.) may accou

The Product may invest up to 70% if its net assets, in fixed income securities and money market instruments from issues of the public or private sector, depending on market opportunities without any constraint in terms of rating or duration. Nevertheless, investment in non "Investment Grade" or non-rated debt securities (i.e. which have a Standard & Poor's rating below A-3 short-term rating or BBB- long-term rating or equivalent) may not exceed 30% of its net assets. The Management Company shall not solely base its investment decisions, risk assessment on the ratings assigned by independent rating agencies but shall also proceed to its own analysis of credit.

The Product may invest up to 10% of its net assets in securities which qualify as distressed securities (i.e. which have a Standard & Poor's notation equivalent or below CCC long-term rating or equivalent). In all cases, the Product will not invest in securities which qualify as "in default" at the time of the investment or during their lifetime in the portfolio. Fixed income securities which may be downgraded as "in default" will be disposed of as soon as possible with due regards to interest of shareholders. The Product may invest in securities with embedded derivatives such as convertible bonds and up to 5% of its net assets in contingent convertibles bonds.

Up to 10% of its net assets, the Product may invest in units and/or shares of UCITS and/or other UCIs including ETFs

In order to achieve the investment objective, the Product may also invest up to 100% of its net assets in financial derivative instruments for the purpose of hedging or increasing equity exposure, interest rate risk or currency risk without seeking exposure.

The Product is actively managed and uses the benchmark for the calculation of the performance fee and performance comparison purposes. This means the Management Company is taking investment decisions with the intention of achieving the Product's investment objective; this may include decisions regarding asset selection and overall level of exposure to the market. The Management Company is not in any way constrained by the benchmark in its portfolio positioning. The deviation from the benchmark may be complete or significant.

This is an accumulation share.

#### INTENDED RETAIL INVESTORS

The Product is intended for retail investors who have no financial knowledge or experience of the financial sector. The Product is intended for investors who can with stand capital losses and who do not require a capital guarantee.

### **OTHER INFORMATION**

 $The \, Depositary \, is \, BNP \, Paribas, Luxembourg \, Branch.$ 

The full prospectus and lastest key information document, as well as lastest annual report are available on the website www.dnca-investments.comordirectlyfromthemanufacturer:DNCAFinanceat19PlaceVendôme75001Paris.

The NAV is available on the website: www.dnca-investments.com.

## What are the risks and what could I get in return?

#### **RISK INDICATOR**



Lowerrisk

Higherrisk



The risk indicator assumes you keep the product for 5 years.

The risk can be significantly different if you cash in at an early stage and you may get backless.

The summary risk indicator is a guide to the level of risk of this Product compared to other products. It shows how likely it is that the Product will lose money because of movements in the markets or because we are not able to pay you. The essential risks of the Product lie in the possibility of depreciation of the securities in which the Product is invested.

We have classified this Product as 4 out of 7, which is a medium risk class.

This rates the potential losses from future performance at a medium level, and poor market conditions could impact our capacity to pay you.

Other risks materially relevant to the Product and which could lead to a fall in the net asset value to which the indicator gives too little consideration: counterparty risk and operational risk.

This Product does not include any protection from future market performance, so you could lose some or all of your investment.

#### **PERFORMANCE SCENARIOS**

The figures shown include all the costs of the Product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back. What you will get from this Product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the Product over the last 10 years. Markets could develop very differently in the future.

The stress scenario shows what you might get back in extreme market circumstances. What you get will depend on market trends and how long you keep the Product.

| Recommended holding period:<br>Example investment | 5 years<br>EUR10 000       |                             |
|---|----------------------------|-----------------------------|
|   | lfyou exit after<br>1 year | lfyou exit after<br>5 years |

#### **SCENARIOS**

| Minimum      | $There is no {\it minimum guaranteed return.} You {\it could lose some or all of your investment.}$ |                    |                    |
|--------------|---|--------------------|--------------------|
| Stress       | What you might get back after costs  Average return each year                                       | EUR 6630<br>-33.7% | EUR 5400<br>-11.6% |
| Unfavourable | What you might get back after costs  Average return each year                                       | EUR 8480<br>-15.2% | EUR 9050<br>-2.0%  |
| Moderate     | What you might get back after costs Average return each year  | EUR 10290<br>2.9%  | EUR 10930<br>1.8%  |
| Favourable   | What you might get back after costs Average return each year  | EUR 11940<br>19.4% | EUR 13620<br>6.4%  |

- The unfavourable scenario occurred for an investment in the Product between March 2015 and March 2020.
- The moderate scenario occurred for an investment in the Product between September 2018 and September 2023.
- The favourable scenario occurred for an investment in the Product between March 2019 and March 2024.

## What happens if DNCA Finance is unable to pay out?

The Product is a co-ownership of financial instruments and deposits separate from DNCA Finance. In the event of the default of DNCA Finance, the assets of the Product held by the depositary will not be affected. In the event of default by the depositary, the risk of financial loss of the Product is mitigated due to the legal segregation of the depositary's assets from those of the Product.

#### What are the costs?

The person advising on or selling you this Product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

#### **COSTS OVER TIME**

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the Product and how well the Product does.

The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed

- In the first year you would get back the amount that you invested (0% annual return). For the other holding periods we have assumed the Product performs as shown in the moderate scenario.
- -FUR10000 is invested.

### Investment of EUR 10 000 If you exit after 1 year If you exit after 5 years

|                        | <u> </u> |                |
|------------------------|----------|----------------|
| Total costs            | EUR 456  | EUR1694        |
| Annual cost impact (*) | 4.6%     | 3.0% each year |

<sup>\*</sup> The annual cost impact illustrates how costs reduce your return each year over the holding period. For example, it shows that if you exit at the recommended holding period your average return per year is projected to be 4.8% before costs and 1.8% after costs.

We may share part of costs with the person selling you the Product to cover the services they provide to you. These figures include the maximum distribution fee and which amount of 100% of costs. This person will inform you of the actual distribution fee.

| One-off costs upon entry or exit |   | If you exit after<br>1 year |
|----------------------------------|---|-----------------------------|
|                                  | Up to 2.00% of the amount you pay in when entering this Investment. This is the |                             |

| Entry costs   | Up to 2.00% of the amount you pay in when entering this Investment. This is the most you will be charged. The person selling you the Product will inform you of the actual charge.  | Upto EUR 200 |
|---|---|--------------|
| Exit costs  | We do not charge an exit fee for this Product.  | None         |
| Ongoing costs taken each year                               |   |              |
| Management fees and other administrative or operating costs | 2.30% of the value of your investment per year. This is an estimate based on actual costs over the last year.   | EUR230       |
| Transaction costs   | O.15% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the Product. The actual amount will vary depending on how much we buy and sell. | EUR15        |

#### Incidental costs taken under specific conditions

| Performancefees | 20.00% of the positive performance net of any fees above the composite index 25% MSCI World NR EUR + 25% MSCI Europe NR EUR + 50% Bloomberg Euro Govt Inflation Linked 1-10 years. The actual amount will vary depending on how well your investment performs. The aggregated cost estimation above includes the average over the last 5 years. | EUR11 |
|-----------------|---|-------|
|-----------------|---|-------|

# How long should I hold it and can I take my money out early?

#### Recommended holding period: 5 years.

 $Shareholders\,may\,redeem\,shares\,on\,demand\,and\,executed\,on\,each\,NAV\,calculation\,and\,publication\,day\,before\,12.00\,noon\,(Luxembourg\,time).$ 

 $The \, recommended \, holding \, period \, was \, chosen \, depending \, on \, the \, asset \, class, investment \, strategy \, and \, risk \, profile \, of \, the \, Product, \, to \, enable \, it \, to \, achieve \, its \, investment \, objective \, while \, minimizing \, the \, risk \, of \, loss.$ 

You can redeem all or part of your investment at any time before the end of the recommended holding period, or hold it longer. There are no penalties for early divestment. However, if you request redemption before the end of the recommended holding period, you may receive less than expected.

The Product has a redemption capping system know as « Gates » described in the prospectus.

# How can I complain?

If you have any compliants about the Product, you can send a written request with a description of the problem either by e-mail dnca@dnca-investments.comortothefollowingaddress:DNCAFinance,19PlaceVendôme,75001Paris.

### Other relevant information

The Product promotes environmental or social and governance (ESG) criteria within the meaning of Article 8 of Regulation (EU) 2019/2088 on sustainability reporting in the financial services sector ("SFDR Regulation").

The Product's prospectus and the latest key information document, as well as the latest annual report and information on past performance, can be obtained free of charge from the website of the manufacturer: www.dnca-investments.com.

When this Product is used as a unit-linked carrier in a life insurance or capitalization contract, additional information on this contract, such as the costs of the contract, which are not included in the costs indicated in this document, the contact in the event of a claim and what happens in the event of default by the insurance company, are presented in the key information document for this contract, which must be provided by your insurer or broker or any other insurance intermediary in accordance with its legal obligation.